SALT LAKE CITY, Nov. 24, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (NasdaqGM:BSDM - News) today reported that the National Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma (V.2.2008) issued by the National Comprehensive Cancer Network (NCCN) include reference to the preliminary results from a 341 patient phase III randomized multi-center clinical trial (EORTC-62961 and NCT00003052) involving the use of regional hyperthermia and chemotherapy with EIA (etoposide, ifosfamide and adriamycin), as compared to EIA alone. This landmark trial was led by the University Medical School of Grosshadern, Munich, Germany, and patients were contributed by Duke University Medical School, Durham, N.C., Charite University Medical School Berlin, Duesseldorf University Medical School, both in Germany, Haukeland University Medical School Bergen, Norway, and Graz University Medical School, Austria, all of which used the BSD 2000 Deep Regional Hyperthermia System manufactured by BSD Medical Corp. The clinical practice guidelines reference the study results from the ACRO 2007 Meeting Abstracts (Journal of Clinical Oncology 2007;25(18 suppl):10009), which reported that after a median follow-up of 24.9 months, disease-free survival for locally-advanced high-risk soft tissue sarcoma patients receiving regional hyperthermia was 31.7 months vs. 6.2 months for those receiving EIA alone, progression-free survival was 84% vs. 64% respectively for extremity sarcomas and 57% vs. 39% for body wall and abdominal sarcomas, and overall response rate was 28.7% for those receiving regional hyperthermia plus EIA vs. 12.6% for those receiving EIA alone.
